Background: Matrix metalloproteinases (MMPs), MMP-inhibitors (TIMPs), ADAM(TS)s and growth factors are involved in inflammation and tissue damage and repair, all occurring in inflammatory bowel disease (IBD). We studied the impact of anti-inflammatory therapy with infliximab on mucosal expression of these tissue remodeling genes in IBD patients. 
Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling inflammatory bowel diseases (IBD) with increasing prevalence throughout the whole world. IBD occurs mostly in young people and often leads to a greatly decreased quality of life, with (bloody) diarrhea and abdominal pain as major gastrointestinal symptoms.
Despite extensive efforts, the exact pathogenesis of IBD remains unknown. However, it is believed that the chronic intestinal inflammation in IBD is the result of an inappropriate and ongoing activation of the mucosal immune system towards the (normal) luminal microbiota in genetically susceptible individuals. This activation of the mucosal immune system is most likely facilitated by defects in both the intestinal epithelial barrier function ("leaky mucosal barrier") and the mucosal immune system ("loss of immune tolerance") (1).
Chronic intestinal inflammation leads to tissue damage and subsequent tissue repair, and all these events are accompanied by an increased turnover of the extracellular matrix (ECM). Disturbance in the balance between the synthesis and breakdown of ECM components is involved in the pathological findings of IBD, leading to progressive tissue destruction (e.g. ulcers and fistulas) or excessive deposition of collagens (major component of ECM) resulting in fibrosis (2) (a disintegrin and metalloproteinase) and ADAMTSs (ADAMs with thrombospondin type 1 motif), which have both adhesive and proteolytic activities. Growth factors are involved in the modulation of intestinal inflammation and repair during IBD, having a critical role in cellular proliferation, differentiation and angiogenesis (7) . They also promote wound healing by stimulating ECM synthesis, in part by modulating the balance between MMPs and TIMPs (8) . Finally, an intrinsic network of interactions between inflammatory cytokines and growth factors with the balances of proteinases and inhibitors exists in acute and chronic inflammatory diseases, in which tumor necrosis factor (TNF) is a key regulator (9) . These interactions not only include the induction of growth factors and proteases by upstream agonists, such as TNF, but also the activation, potentiation and degradation of growth factors and proteinases by extracellular proteases (3;10) . Infliximab (Remicade; Centocor, Inc., Malvern, PA, USA), a chimeric monoclonal antibody to tumor necrosis factor-alpha (TNF-α), has become the mainstay of therapy in refractory IBD (11) 
MATERIALS and METHODS

MMPs, TIMPs, ADAM(TS)s and growth factors
The gene expression of 23 MMPs, 4 TIMPs and 50 ADAM(TS)s and the expression of 158 genes encoding peptides/proteins with growth factor activity (see A control group with normal mucosa of 12 individuals [6 colon and 6 ileum] who underwent endoscopy for screening for polyps was also included. The patients underwent endoscopy with biopsies from diseased bowel (colon for UC and CDc and ileum for CDi) within a week prior to the first intravenous infliximab infusion of 5 mg/kg body weight. The patients underwent a second endoscopy with biopsies 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if they received a loading dose of infliximab at weeks 0, 2 and 6. The biopsies were taken at sites of active inflammation but at a distance of ulcerations. In the case of healing at control endoscopy, the biopsies were obtained in the areas where lesions were present before therapy. The endoscopist was not blinded to treatment. Half of the biopsies were immediately snap-frozen in liquid nitrogen and stored at -80°C until RNA isolation, except for the biopsies from 1 CDc patient after infliximab treatment because of poor technical quality. The rest of the biopsies were fixed in Carnoy's fixative for up to 5 hours and then dehydrated, cleared and paraffin-embedded.
Supplementary
Haematoxylin-eosin stained slides from the paraffin blocks of each patient were used to score the chronic intestinal inflammation, using a previously reported histological scoring system for UC (12) and for CD (13) .
The response to infliximab therapy was assessed at the time of the second endoscopy, based on endoscopic and histologic findings. In the colon, the response was defined as a complete endoscopic mucosal healing (absence of ulcers) with a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 8 decrease of at least 3 points on the histological score for CDc (13) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for UC (12;14) . Patients who did not achieve this healing were considered non-responders although some of them showed endoscopic and/or histologic improvement. Of the 43 IBDc patients, we scored 20 responders (8 UC and 12 CDc) and 23 non-responders (16 UC and 7 CDc). When the same response criteria of CDc were used for CDi, there was only one patient who showed in the ileum a complete endoscopic and histologic healing. Therefore, we used response criteria with lower stringency than complete healing in CDi. Patients with a clear improvement of the ulcerations and a decrease on the histological score (13) were defined as responders. Of the 18 CDi patients, 8 were (partial) responders and 10 were non-responders.
The characteristics of age, sex and smoking were compared between patients and controls. These comparisons were performed with the Mann-Whitney U-test for continuous variables and Fisher's exact test for categorical variables, using SPSS software (Chicago, IL) ( Table 1) . A p-value ≤ 0.01 was considered significant.
Whole-genome gene expression analysis
As previously described (15) , total RNA was extracted from the biopsy specimens and used to analyze the gene expression via Affymetrix Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA), which are comprised of 54 675 probe sets covering the whole genome. The microarray data have been submitted in MIAME (Minimum Information About a Microarray Experiment) format to the Gene Expression Omnibus database (series accession number GSE16879).
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Protein expression by immunohistochemistry
To localize MMP1, MMP3, TIMP1 and REG1A in the intestinal mucosa, immunohistochemistry was performed on 5 µm-thick sections that were cut from paraffin blocks of formalin-fixed endoscopic biopsies from IBD patients and control individuals. After drying, deparaffinization and rehydration, epitope retrieval was performed at low pH for MMP1 and TIMP1, and at high pH for MMP3 and REG1A 
Zymography analysis
Snap-frozen mucosal biopsies from a subset of active CDi patients (n=3) and IBDc patients (n=3) before and after treatment with infliximab, as well as control samples (3 ileum, 2 colon) were investigated with gelatin zymography analysis as described previously (21) . Briefly, the weight of the biopsies was determined and 500 µl of lysis buffer was added (50 mM Tris, 0.5 M NaCl, 10 mM CaCl 2 , 0.5% Triton-X 100, 
Gelatin degradation assay
The gelatin degradation assay was performed on snap-frozen mucosal biopsies from a subset of active CDi patients (n=3) and IBDc patients (n=3) before and after treatment with infliximab, as well as control samples (3 ileum, 3 colon). First, proteins were extracted from the biopsy samples in 500 µl assay buffer (150 mM NaCl, 50 mM Tris, 5 mM CaCl 2 , 0.05% Tween20). Next, the net gelatinolytic activity was measured with the use of a previously described gelatin degradation assay (23).
Briefly, the samples were added (duplicates) to a 96-well plate (chimney, black, clear bottom, Greiner Bio-one, Frickenhausen, Germany) and DQ TM -gelatin (Invitrogen, Carlsbad, CA, USA) was added to a final concentration of 2.5 µg/ml. Immediately thereafter, the plate was placed in a fluorescence reader (FL600 Microplate fluorescence reader, Biotek, Highland Park, IL, USA) and fluorescence was measured every 10 min for 4h at 37°C.
ETHICAL CONSIDERATIONS
The study was carried out at the University Hospital Gasthuisberg in Leuven (ClinicalTrials.gov number, NCT00639821). Written informed consent was obtained from all individuals and the study was approved by the University Hospital Ethics
Committee. 
RESULTS
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Gene expression of tissue remodeling genes in IBD intestinal mucosa before and after first infliximab therapy
The intestinal mucosal gene expression microarray profiles were compared between normal controls, patients pre-and post-infliximab therapy in UC, CDc, IBD colitis (IBDc; UC and CDc together) and CDi.
In the current microarray study, we studied the intestinal mucosal gene expression of table 3 ). In the comparative analyses, the filtered probe sets with > 2-fold change and FDR < 0.05 were considered biologically significant. Additionally, we found that the characteristic age was significantly different between IBD patients and controls (Table 1) . To investigate if age has an impact on the expression of the tissue remodeling genes in IBD and controls, LIMMA analysis between IBD patients (before therapy) and controls was performed with age as confounding factor. The results of the comparative analysis with age as confounder were similar as for the analysis without age as confounding factor. So there was no impact of the age on the 
Expression of MMPs, TIMPs and ADAM(TS)s
First, we studied whether differences existed in gene expression of MMPs, TIMPs and ADAM(TS)s in active UC as compared with active CDc. We observed no significant gene expression differences at baseline (= pre-infliximab therapy) in inflamed colon between UC and CDc (Supplementary table 3) . Second, we investigated the differential expression in MMP, TIMP and ADAM(TS) genes at baseline between active CDc and active CDi. Only MMP12 expression was more than 2-fold significantly downregulated at baseline in active CDi as compared to active CDc (Supplementary table 3) .
Third, we investigated the differential gene expression of MMPs, TIMPs and ADAM(TS)s in inflamed mucosa of IBD patients and the effect of infliximab therapy on the expression of these genes (Table 2 and 3). In IBDc, the gene expression levels of MMP1-3, MMP7, MMP9-10, MMP12, MMP19, TIMP1-2, ADAM9, ADAM19, ADAM28, ADAMTS1 and ADAMTS9 were more than 2-fold significantly increased, whereas only MMP28 gene expression was more than 2-fold significantly decreased at baseline in inflamed colon as compared to control colons. Most of the MMP and TIMP genes upregulated at baseline in active IBDc decreased more than 2-fold significantly after infliximab therapy in IBDc responders when compared to baseline, and MMP28 expression was more than 2-fold significantly increased ( Table 2 ). In contrast, no significant changes of these genes were observed in IBDc nonresponders after therapy when compared to their baseline samples (Supplementary and MMP12 (28.72x) was much higher than the fold change of the significant TIMPs [TIMP1 (11.51x) and TIMP2 (2.16x) ( Table 2 ). In IBDc responders after therapy versus control colons, the fold change for both MMPs and TIMPs was around 1
( Table 2 ).
In CDi, the gene expression levels of MMP1, MMP3, MMP7, MMP10 and TIMP1
were more than 2-fold significantly upregulated, whereas only ADAMDEC1 gene expression was more than 2-fold significantly downregulated at baseline in inflamed ileum as compared to control ileums. After infliximab therapy, no genes remained dysregulated in CDi responders as compared to control ileums, whereas the expression levels of MMP1, MMP3 and TIMP1 remained more than 2-fold significantly upregulated in CDi non-responders when compared to control ileums (Table 3) .
Moreover, the ratio between the fold change of MMP1 and TIMP1, MMP3 and TIMP1, and MMP10 and TIMP1 in active CDi before therapy vs. control ileums was also increased (Table 3 ) as in IBDc before therapy.
Next, we studied the correlation of the expression of the MMP, TIMP and ADAM(TS) genes that were dysregulated at baseline in active disease with the gene expression 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 16 of granulocyte markers (S100A8, S100A9 and S100A12), an inflammatory marker (interleukin 8 (IL8)) and an epithelial marker (villin 1 (VIL1)). The correlations were analyzed with the Spearman's Rank Correlation test using the microarray log2 mRNA expression values, and a p-value ≤ 0.01 was considered significant (Supplementary   table 5 ). The colon (n=91) and ileum (n=42) samples were analysed separately. A highly positive significant correlation was found for the mRNA levels for all upregulated MMPs, TIMPs and ADAM(TS)s with the mRNA levels of S100A8, S100A9, S100A12 and IL8 for both colon and ileum samples. A negative significant correlation was seen between the colonic mRNA levels of the downregulated MMP28
and VIL1, and between the ileal mRNA levels of the downregulated ADAMDEC1 and
VIL1.
Expression of growth factor genes
Two rationales incited us to study growth factor gene expression levels in intestinal biopsies. First, many balances between MMPs and inhibitors are regulated by growth factors, and ADAM(TS)s have a prominent role in growth and development. Second, IBD results in epithelial tissue regenerative processes and healing processes involve growth regulating cytokines.
First, we studied the differential gene expression of growth factors at baseline in inflamed colon between active UC and active CDc, and we found no significant differences in gene expression of growth factors at baseline between active UC and active CDc (Supplementary table 3) . Second, the differential gene expression of growth factors was studied at baseline between active CDc and active CDi. At baseline, the gene expression levels of FGF9, MACC1, MST1 and PDGFC were more than 2-fold significantly higher, and AREG, BMP2, CTGF and LEFTY1 gene and TYMP was more than 2-fold significantly upregulated, whereas only TGFA gene expression was more than 2-fold significantly downregulated before infliximab therapy in inflamed colon as compared to control colons. The expression of many growth factor genes which were upregulated at baseline in inflamed IBD colon were no longer significantly upregulated after therapy in IBDc responders when compared to control colons. As an exception, we observed that the colonic expression levels of AREG and JAG1 remained more than 2-fold significantly higher in IBDc responders after infliximab therapy as compared to control levels in the colon ( Table 5 ). In contrast, most of the growth factor dysregulations observed at baseline in inflamed IBDc colon remained dysregulated after infliximab therapy in IBDc non-responders ( Table 5) . Of notice, the gene expression level of REG1A was more than 70 times higher in IBDc when compared to control colons and after infliximab treatment the expression was restored in IBDc responders but not in IBDc non-responders.
In CDi, only TFF1 mRNA expression was more than 2-fold significantly increased at baseline in inflamed ileum when compared to control ileums. In contrast with inflamed CDc colon, AGT mRNA expression levels were more than 2-fold significantly decreased at baseline in inflamed CDi ileum versus control ileums. After infliximab therapy, only AGT expression remained downregulated in CDi responders, and TFF1 and AGT expression remained significantly dysregulated in CDi non-responders as compared to control ileums (Table 6) .
Finally, all upregulated growth factor genes at baseline in active IBD correlated positively with the granulocyte markers (S100A12, S100A8 and S100A9) and the inflammatory marker IL8, except for the colonic mRNA levels of AREG, HBEGF, JAG1 and the ileal AGT mRNA levels. A strong positive significant correlation was found between the colonic mRNA levels of the downregulated TGFA and the epithelial marker VIL1, and no correlation was seen between the ileal mRNA levels of the downregulated AGT and VIL1 (Supplementary table 5) .
Validation of selected microarray data by qRT-PCR
We were able to confirm with the use of qRT-PCR the gene expression microarray results for MMP1, MMP28, TIMP1, ADAM9, TFF1, TGFB1, the ratio MMP1/TIMP1 (Figures 1 and 2 , and Supplementary table 6) between controls and IBD patients before and after treatment.
As compared to control colons, the gene expression levels of MMP1, TIMP1, ADAM9
and TGFB1 were all significantly increased, and only MMP28 was significantly decreased in the inflamed colon of active IBDc patients. None of these genes remained significantly dysregulated after therapy in IBDc responders vs. control colons, whereas in IBDc non-responders the gene expression of MMP1, TIMP1, ADAM9 and MMP28 remained significantly dysregulated after therapy when compared to control colons. Moreover, the ratio of MMP1/TIMP1 gene expression was significantly increased in active IBDc versus control colons, and this imbalance was restored after therapy in IBDc responders when compared to control colons. 
Protein expression of MMP1, MMP3, REG1A and TIMP1 in ileal and colonic biopsies
Immunohistochemistry was performed to localize MMP1, MMP3, REG1A and TIMP1
in the intestinal mucosa of controls and IBD patients with active and inactive disease.
In normal mucosa MMP1 was expressed in the cytoplasm of primitive cells at the base of the crypts (Figure 3A) , whereas active IBD mucosa showed an increased expression of MMP1 in immature and surface epithelium cells according to the regeneration of the epithelial layer ( Figure 3A) . Moreover, MMP1 expression was found in endothelial cells of active IBD patients nearby active inflammation areas. In normal mucosa, MMP3 was detected in mononuclear inflammatory cells ( Figure 3B ).
In active IBD mucosa, there was an increased expression of MMP3 according to the increased amount of mononuclear inflammatory cells ( Figure 3B) . REG1A was expressed mainly in the Paneth cells at the base of the crypts in normal mucosa ( Figure 3C) , whereas an enhanced expression of REG1A was seen in immature and surface epithelium cells of active IBD patients ( Figure 3C ). TIMP1 expression was seen in enteroendocrine cells at the base of the crypts, but no clear differences could 
Gelatinase levels and net gelatinolytic activities before and after treatment with infliximab
Zymography analysis was performed to determine gelatinase (MMP9 and MMP2) levels in mucosal biopsies taken from 3 IBDc and 3 CDi responder patients before and after infliximab, and 5 controls (3 ileum, 2 colon). In figure 4 and supplementary figure 1, a clear trend for higher gelatinase levels was seen before infliximab therapy when compared to levels after therapy or control levels.
Interestingly, no NGAL-MMP9 or activated MMP9 levels were measured in control tissues. In addition, a gelatin degradation assay was performed to determine the net gelatinolytic activity present in the mucosal biopsies. Overall, a trend was seen for elevated gelatinolytic activity levels before infliximab treatment and a decrease to control activity levels after treatment ( Figure 5) . Moreover, two patients (1 CDi and 1 IBDc responder) had markedly high activity levels before infliximab.
DISCUSSION
In IBD a disturbed and high intestinal turnover is observed during the sequence of inflammation, tissue destruction and repair, resulting in tissue morphological changes (e.g. ulcers, fibrosis) (2;4;7;24;25). MMPs, ADAM(TS)s, TIMPs and growth factors play a major role in this tissue remodeling process. Achievement of mucosal healing in IBD responders to infliximab treatment allowed us to identify, during the evolution of the healing process, the changes that occur with healing in mediators of mucosal damage and repair in IBD. in UC and/or CDc as compared to control colons. As earlier described (26), the most upregulated gene in IBDc inflamed colon is the cell proliferation gene REG1A (>50-fold). Besides IBD, upregulated REG1A is also associated with type 1 diabetes, celiac disease and pancreatic cancer (27-29), and has been proposed to act as a mitogenic and/or an anti-apoptotic factor in the development of UC-associated neoplasia (30). Moreover, the analysis of protein levels and localization with immunohistochemistry demonstrated that REG1A was expressed by Paneth cells in normal conditions, whereas in active disease REG1A levels increased and the expression shifted towards all epithelial cells of the mucosal crypts. These data confirm previous studies, whereby REG1A gene and protein expression levels were studied in inflamed and control colonic mucosa(31;32). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (n=6). These data suggested that higher net gelatinolytic activity was present in mucosal biopsies before infliximab and the activity decreased to control levels after infliximab. Zymography analysis performed in this study showed that gelatinase (MMP2 and MMP9) levels had a trend to decrease after infliximab. These data were expected, since previous studies have shown that MMP2 and MMP9 decreased in mucosal biopsies (36) and serum (37) following infliximab therapy in CD.
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Interestingly, 1 CDi and 1 IBDc responder patient had particularly high net gelatinolytic activity levels and these patients also had the highest gelatinase levels as measured by zymography analysis (CDiR1 w0 and UCR1 w0, see supplementary figure 1 ). In addition, these high mucosal gelatinolytric activities normalized to control levels after treatment of with infliximab. This highlights the advantage of using both zymography analysis and a gelatin degradation assay. The combination of the tests enables to give information on presence, in a semiquantitative manner, and activity of the gelatinases in a biological sample (21)).
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